Geron nearly doubles in premarket trading on imetelstat data

|About: Geron Corporation (GERN)|By:, SA News Editor

Geron (GERN) shareholders get great news for imetelstat in myelofibrosis.

Overall response rate: 44%.

CRs: 4

PRs: 1

From the research abstract: "The observed morphologic and molecular remissions confirm selective anti-clonal activity, which has thus far eluded other drugs in MF, including JAK inhibitors. The association between response and spliceosome mutations suggests a broader application for the drug in myeloid malignancies."

GERN +93% premarket